Guiding Next Steps for Patients at Risk of Advanced Fibrosis

Every patient's journey is different. Clinical decisions shouldn't rely on assumptions. Patients with MASLD progress at different rates, and no two clinical pathways are exactly alike. From identifying patients at increased risk to further evaluation, management, and longitudinal monitoring, each step depends on having meaningful clinical information at the right time. LIVERFASt™ provides biopsy-aligned assessment of fibrosis, steatosis, and inflammatory activity, helping clinicians better understand disease severity and support informed patient management. Because every clinical decision shapes the next step in a patient's journey. Learn more about the clinical evidence behind LIVERFASt™: https://lnkd.in/g52CHnaV #ClinicalPathways #ClinicalDecisionMaking #MASLD #MASH #LIVERFASt #LiverHealth #RiskStratification #Fibronostics

As vascular medicine continues to advance, clinical frameworks are becoming increasingly individualized. 🩺 The emphasis is shifting toward understanding the underlying factors that contribute to disease presentation, allowing clinicians to make more informed decisions throughout the diagnostic process. This approach supports greater precision, improves resource utilization, and helps ensure that patients receive the most appropriate evaluation based on their specific circumstances. The future of vascular care is increasingly defined by tailored assessment strategies rather than standardized pathways. 🧭 #VascularMedicine #ClinicalExcellence #HealthcareInnovation #PatientOutcomes #MedicalLeadership

The life science industry has given much attention to generalized myasthenia gravis in recent years, and fortunately this continues. In PatientSight's first Patient Experience Benchmark Report, one of the many gMG journey phases we examined is treatment experience. Here are some findings: - Higher disease severity is associated with worse treatment experience. - Patients on branded treatments don't have significantly better experience scores vs. unbranded/older therapies; however, overall disease severity is higher with newer brands. - Not all brands are equivalent in treatment experience ratings. - Self-administered therapies create a better experience for patients. Progress is being made- there are now a surprising number of treatments available for a rare disease like gMG. In a highly competitive field like this, measuring patient experience across the journey is essential. #MyastheniaGravis #PatientExperience #PatientInsights

Patients with moderate to severe atopic dermatitis are waiting too long for the care they need. AMCP's new Market Insights reveals the top care gaps: delayed diagnosis, limited specialist access, and more. Get expert perspectives on emerging therapies and how to improve patient outcomes. Read the full article here: https://hubs.li/Q04ptPDL0

Why did specialty care get skipped in the first wave of value-based models? Because specialty conditions are harder: fewer patients per condition, more clinical variability, cost spikes that are difficult to predict. But those same qualities are exactly why specialty care has the most room to improve. When a chronic disease has a high and highly variable cost per member, even small gains in early detection produce outsized results. We call these “high beta conditions.” Inflammatory bowel disease is the clearest example in American healthcare today. What other specialties do you think are ready for outcomes-based models? Comment below.

A liver assessment is only valuable if it helps answer one question: What should I do next? For clinicians managing patients with MASLD/MASH, every assessment has the potential to influence the next step in care, whether that means: • Referring a patient for specialist evaluation • Prioritising further diagnostic assessment • Initiating or intensifying lifestyle interventions • Monitoring disease progression over time • Identifying patients who may benefit from emerging therapies LIVERFASt™ was designed to support these everyday clinical decisions by providing biopsy-aligned fibrosis staging, along with steatosis and activity assessment, helping translate laboratory data into clinically meaningful insights. Because clinicians don't just need results. They need information that supports confident decisions and better patient care. Learn more about the clinical evidence behind LIVERFASt™: https://zurl.co/TXJaY #PhysicianPerspective #ClinicalDecisionMaking #MASLD #MASH #LIVERFASt #ClinicalPathways #RiskStratification #LiverHealth #ClinicalEvidence #Fibronostics

Understanding hemodynamics can make a big difference when caring for critically ill patients, especially when trying to sort out what’s driving instability at the bedside. This live CE webinar will review the basics of hemodynamics and connect them to cardiogenic and non-cardiogenic conditions, including ARDS and CHF, with a focus on treatment considerations and real-world clinical application. https://lnkd.in/ex9ff2mk

Understanding hemodynamics can make a big difference when caring for critically ill patients, especially when trying to sort out what’s driving instability at the bedside. This live CE webinar will review the basics of hemodynamics and connect them to cardiogenic and non-cardiogenic conditions, including ARDS and CHF, with a focus on treatment considerations and real-world clinical application. https://lnkd.in/e8Q3RPHX

Less isn't always less. Sometimes, the smallest dose can make the biggest difference. For some patients with mast cell activation, Dr. Ina Stephens (UVA Health) explains that carefully supervised microdosing, using just a fraction of a standard dose, may provide meaningful symptom relief with little to no side effects. While it isn't appropriate for everyone, this approach highlights an important principle in medicine: more isn't always better. The right treatment is about finding the dose that works for the individual patient. Last week's episode of Bendy Bodies explores how thoughtful, personalized treatment strategies can help patients with complex chronic illnesses, including why microdosing may be a valuable option for some people with MCAS. Have you ever needed a lower dose of a medication because your body was especially sensitive? #MastCellActivation #MCAS #HypermobileEDS #ChronicIllness #BendyBodiesPodcast This post is for educational purposes only and is not medical advice. Treatment decisions should always be made with your healthcare provider. VD: Dr. Ina Stephens explains how carefully supervised microdosing may help some patients with mast cell activation by providing symptom relief with minimal side effects while emphasizing the importance of individualized treatment.

Inotropes and Vasopressors in Special Populations with Septic Shock: A Narrative Review Explore this narrative review, providing evidence-based guidance on the use of inotropes and vasopressors in special populations with septic shock. The review highlights practical management considerations to support individualized patient care and improve clinical outcomes. Read the full review to explore the latest recommendations. https://lnkd.in/dUAXVNCw